There's a rumor floating around that President Donald Trump got his hands on an experimental weight-loss drug before it hit the market. The White House wants you to know that's not true.

A STAT News report published Tuesday suggested that Trump had been given Eli Lilly and Co. (LLY)'s retatrutide, a triple-hormone receptor agonist that's still under FDA review. The drug, which targets GIP, GLP-1, and glucagon pathways, has shown some serious weight loss numbers in trials—but it's not approved yet.

The report, citing three anonymous sources, claimed the drug may have been administered to Trump, who recently turned 80. The story pointed to an FDA compassionate use application for a 79-year-old patient with refractory obesity—a severe condition where someone can't lose and keep off at least 5% of body weight despite trying multiple treatments. The implication was clear.

But White House senior deputy press secretary Kush Desai wasn't having it. In a post on X, he flatly denied the claim, writing, "…this application was not for the President," and telling reporters to stop printing baseless speculation.

Trump's History With GLP-1 Drugs

This isn't the first time Trump's relationship with weight-loss drugs has come up. In a January interview with The New York Times, Trump said he had never used GLP-1 drugs like Wegovy or Ozempic, though he joked that he "probably should."

And in November, Trump announced agreements with Eli Lilly and Novo Nordisk A/S (NVO) to significantly lower the prices of their GLP-1 obesity and diabetes drugs while expanding Medicare and Medicaid coverage for the treatments. So if anything, he's been working to make these drugs more accessible, not sneaking them through back channels.

Retatrutide: The Drug That's Making Waves

So what's the big deal about retatrutide? It's a triple hormone receptor agonist—meaning it hits three different pathways (GIP, GLP-1, and glucagon) to promote weight loss. In May, a study showed that patients taking the 12 mg dose lost an average of 70.3 pounds, or 28.3% of their body weight. That's a lot.

In June, Eli Lilly highlighted the drug's benefits for women across all stages of menopause, based on analyses of more than 1,500 women in the ATTAIN-1 and ATTAIN-2 trials.

Analyst William Blair called retatrutide an "ultra-high-potency" obesity treatment. Meanwhile, analyst Andy Hsieh noted that, based on cross-trial comparisons, retatrutide delivered about 3 percentage points more weight loss than Eli Lilly's Zepbound after 72 weeks—though investors had hoped for a bigger gap. The 9 mg dose slightly edged out Zepbound's highest dose, while the 4 mg dose landed somewhere between Zepbound and Novo Nordisk's Wegovy.

So the drug is promising, but it's not approved yet. And for now, the White House is clear: it's not for the President.